These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6330842)

  • 21. [Studies on new attenuated strains of type I live poliovirus vaccine. I. Development of Zhong I9 strain].
    Chen TQ; Li CZ; Ni SF; Ji GF; Shi M; Ye ZZ; Guo R; Dong DX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1983 Oct; 5(5):280-4. PubMed ID: 6329533
    [No Abstract]   [Full Text] [Related]  

  • 22. Re: world wide experience with inactivated poliovirus vaccine.
    Arya SC; Agarwal N
    Vaccine; 2009 Jan; 27(1):1. PubMed ID: 18952133
    [No Abstract]   [Full Text] [Related]  

  • 23. Maxwell Finland lecture: viral vaccines and their ways.
    Horstmann DM
    Rev Infect Dis; 1979; 1(3):502-16. PubMed ID: 399363
    [No Abstract]   [Full Text] [Related]  

  • 24. A comparative study of reactogenicity and immunogenicity of an oral and an inactivated polio vaccine.
    Borcić B; Dobrovsak-Sourek V; Kaić B; Ljubicić M
    Acta Med Croatica; 1998; 52(3):155-8. PubMed ID: 9818437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Vaccination against poliomyelitis in France. 1983 experience and new trends].
    Celers J
    Ann Pediatr (Paris); 1984 Jun; 31(6):471-5. PubMed ID: 6465800
    [No Abstract]   [Full Text] [Related]  

  • 26. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
    Haastrup E; Thierry-Carstensen B; Jensen AM; Stellfeld M; Heilmann C
    Vaccine; 2004 Feb; 22(8):958-62. PubMed ID: 15161072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivated vaccines based on alternatives to wild-type seed virus.
    Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E
    Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325
    [No Abstract]   [Full Text] [Related]  

  • 30. Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT.
    Parkkali T; Stenvik M; Ruutu T; Hovi T; Volin L; Ruutu P
    Bone Marrow Transplant; 1997 Oct; 20(8):663-8. PubMed ID: 9383230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current advances in viral diagnostic technology applicable to polio vaccination and diagnosis.
    Chernesky MA
    Rev Infect Dis; 1984; 6 Suppl 2():S525-7. PubMed ID: 6330851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Worldwide eradication of poliomyelitis].
    Rasch G; Schreier E; Kiehl W; Kurth R
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
    Herremans TM; Reimerink JH; Buisman AM; Kimman TG; Koopmans MP
    J Immunol; 1999 Apr; 162(8):5011-8. PubMed ID: 10202050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antigenicity determination of inactivated poliovirus--the micro-neutralization inhibition test].
    Jiang SD; Pye D
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Aug; 7(4):309-12. PubMed ID: 3011295
    [No Abstract]   [Full Text] [Related]  

  • 35. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
    Laassri M; Lottenbach K; Belshe R; Rennels M; Plotkin S; Chumakov K
    J Infect Dis; 2006 May; 193(10):1344-9. PubMed ID: 16619180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stopping poliovirus vaccination after eradication: issues and challenges.
    Wood DJ; Sutter RW; Dowdle WR
    Bull World Health Organ; 2000; 78(3):347-57. PubMed ID: 10812731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.
    Ivanov AP; Dragunsky EM; Chumakov KM
    J Infect Dis; 2006 Feb; 193(4):598-600. PubMed ID: 16425140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experiences of vaccination with inactivated poliovirus vaccine in Sweden.
    Böttiger M
    Dev Biol Stand; 1981; 47():227-32. PubMed ID: 7227652
    [No Abstract]   [Full Text] [Related]  

  • 39. Polio antibodies in students before and after vaccination with Salk vaccine.
    Savonen K; Penttinen K; Lapinleimu K
    J Am Coll Health Assoc; 1966 Oct; 15(1):71-7. PubMed ID: 5915795
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of injectable and oral polio vaccines in polio eradication.
    John J
    Expert Rev Vaccines; 2009 Jan; 8(1):5-8. PubMed ID: 19093765
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.